Ice 3682

Drug Profile

Ice 3682

Alternative Names: Ice-3682; JNJ 42503682

Latest Information Update: 04 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Janssen Pharmaceuticals
  • Developer Ice Therapeutics
  • Class Analgesics; Small molecules
  • Mechanism of Action TRPM8 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain

Most Recent Events

  • 04 Jul 2017 Ice Therapeutics in-licenses Ice 3682 from Janssen Pharmaceuticals before July 2017 (FutuRx website, July 2017)
  • 04 Jul 2017 Preclinical trials in Neuropathic pain in Israel (PO) before July 2017 (FutuRx website, July 2017)
  • 04 Jul 2017 Ice Therapeutics announces intention to submit IND/CTA for Neuropathic pain (FutuRx website, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top